Shares of iBio, Inc. (NYSEMKT:IBIO – Get Free Report) traded up 8.3% during trading on Friday . The stock traded as high as $2.35 and last traded at $2.35. 1,928,910 shares were traded during trading, an increase of 1,604% from the average session volume of 113,212 shares. The stock had previously closed at $2.17.
iBio Stock Performance
The company has a debt-to-equity ratio of 0.04, a quick ratio of 0.91 and a current ratio of 0.91. The company has a market cap of $60.71 million, a price-to-earnings ratio of -1.94 and a beta of 1.14. The stock’s fifty day simple moving average is $1.61 and its two-hundred day simple moving average is $1.10.
About iBio
iBio, Inc is a clinical-stage biotechnology company that develops recombinant proteins and vaccine candidates using proprietary plant-based expression systems. Headquartered in Bryan, Texas, the company leverages its Fast Expression System Technology (FAST) and LAMP™ molecular farming platforms to accelerate the design and production of complex biologics. These platforms capitalize on Nicotiana benthamiana plants as biofactories, enabling rapid, scalable expression of target proteins without the need for mammalian cell cultures.
The company’s pipeline includes vaccine candidates against viral pathogens and therapeutic proteins for immuno-oncology and infectious diseases.
Recommended Stories
- Five stocks we like better than iBio
- Wall Street Stockpicker Names #1 Stock of 2026
- Do not delete, read immediately
- How a Family Trust May Be Able To Help Preserve Your Wealth
- A U.S. “birthright” claim worth trillions – activated quietly
- Claim Your Share of $5.39 BILLION in AI Equity Checks
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
